News

Filter

Current filters:

Cardio-vascularMultaq

1 to 9 of 19 results

FDA strengthens warnings on Sanofi’s Multaq; Aubagio disappoints

20-12-2011

The US Food and Drug Administration (FDA) has completed a safety review of French drug major Sanofi’s…

AubagioCardio-vascularMultaqNeurologicalPharmaceuticalRegulationResearchSanofi

EMA recommends restricting use of Sanofi AF drug Multaq, but sees positive benefit-risk in some patients

23-09-2011

There was mixed news for French drug major Sanofi (Euronext: SAN) yesterday, when the European Medicines…

Cardio-vascularEuropeMultaqPharmaceuticalRegulationSanofi

US FDA now joins in probe of Sanofi’s Multaq safety

25-07-2011

The US Food and Drug Administration says it is reviewing data from a clinical trial that was evaluating…

Cardio-vascularMultaqNorth AmericaPharmaceuticalRegulationSanofi

Mixed Ph III results for Sanofi MS drug candidate Lemtrada; EMA to broaden review of Multaq

12-07-2011

French drug major Sanofi (Euronext: SAN) and its US biotech subsidiary Genzyme have announced mixed top-line…

AlemtuzumabBiotechnologyCardio-vascularEuropeGenzymeLemtradaMultaqPharmaceuticalRegulationResearchSanofi

CV events halt Sanofi Multaq trial; Merck KGaA drops Idera cancer drug on safety concerns

08-07-2011

In two clinical disappointments announced yesterday, French drug major Sanofi (Euronext: SAN) and Germany’s…

Cardio-vascularIdera PharmaceuticalsMerck KGaAMultaqOncologyPharmaceuticalResearchSanofi

US FDA warns on acute liver failure with Sanofi-Aventis Multaq

17-01-2011

The US Food and Drug Administration on Friday notified health care professionals and patients about cases…

Cardio-vascularMultaqNorth AmericaPharmaceuticalRegulationSanofi-Aventis

1 to 9 of 19 results

COMPANY SPOTLIGHT

Menarini

Back to top